Literature DB >> 19963024

Integration of virtual screening with high-throughput screening for the identification of novel Rho-kinase I inhibitors.

Li-Li Gong1, Lian-Hua Fang, Jian-Hao Peng, Ai-Lin Liu, Guan-Hua Du.   

Abstract

Rho-kinase inhibitors are effective candidates for the treatment of neural and cardiovascular disorders. The present paper reports the discovery of a novel class of ROCK-I inhibitors by integrating virtual screening with high-throughput screening methods. We developed common-feature pharmacophore models based on known representative ROCK inhibitors and employed them to screen a database of 12,280 compounds. We then applied a LigandFit model to reduce the number of hits. A new high-throughput screening model based on Kinase-Glo Luminescent Kinase Assay was established to identify inhibitors observed among the virtual screening models. Ten hits were found to have larger than 70% inhibition at 10 micromol l(-1) and were worthy of further investigation. Copyright 2009 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19963024     DOI: 10.1016/j.jbiotec.2009.12.003

Source DB:  PubMed          Journal:  J Biotechnol        ISSN: 0168-1656            Impact factor:   3.307


  6 in total

1.  In silico prediction of ROCK II inhibitors by different classification approaches.

Authors:  Chuipu Cai; Qihui Wu; Yunxia Luo; Huili Ma; Jiangang Shen; Yongbin Zhang; Lei Yang; Yunbo Chen; Zehuai Wen; Qi Wang
Journal:  Mol Divers       Date:  2017-08-02       Impact factor: 2.943

Review 2.  Discovery of novel inhibitors for the treatment of glaucoma.

Authors:  Kishore Cholkar; Hoang M Trinh; Dhananjay Pal; Ashim K Mitra
Journal:  Expert Opin Drug Discov       Date:  2015-01-09       Impact factor: 6.098

3.  DL0805-2, a novel indazole derivative, relaxes angiotensin II-induced contractions of rat aortic rings by inhibiting Rho kinase and calcium fluxes.

Authors:  Tian-Yi Yuan; Yu-Cai Chen; Hui-Fang Zhang; Li Li; Xiao-Zhen Jiao; Ping Xie; Lian-Hua Fang; Guan-Hua Du
Journal:  Acta Pharmacol Sin       Date:  2016-04-04       Impact factor: 6.150

Review 4.  Novel Insights into the Roles of Rho Kinase in Cancer.

Authors:  Lei Wei; Michelle Surma; Stephanie Shi; Nathan Lambert-Cheatham; Jianjian Shi
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2016-01-02       Impact factor: 4.291

5.  The vasorelaxant mechanisms of a Rho kinase inhibitor DL0805 in rat thoracic aorta.

Authors:  Lili Gong; Jianhao Peng; Lianhua Fang; Ping Xie; Kun Si; Xiaozhen Jiao; Liping Wang; Guanhua Du
Journal:  Molecules       Date:  2012-05-18       Impact factor: 4.411

6.  Design, synthesis and antitumor activity of 5-trifluoromethylpyrimidine derivatives as EGFR inhibitors.

Authors:  Yaqing Zuo; Rongrong Li; Yan Zhang; Guochen Bao; Yi Le; Longjia Yan
Journal:  J Enzyme Inhib Med Chem       Date:  2022-12       Impact factor: 5.756

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.